RAS(ON) Therapies on the Horizon to Address KRAS Resistance: Highlight on a Phase III Clinical Candidate Daraxonrasib (RMC-6236)
Zonghui Ma, Mingxiang Zhou, Qiang Shen, Jia Zhou
Topics & Concepts
ChemistryKRASPhase (matter)Computational biologyCancer researchBiochemistryMutationOrganic chemistryGeneMedicineBiologyProtein Kinase Regulation and GTPase SignalingAdenosine and Purinergic SignalingRetinoids in leukemia and cellular processes